SCOL Stock Overview
A clinical-stage biotechnology company, discovers and develops medicines for the treatment of cancer. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Scandion Oncology A/S Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.063 |
| 52 Week High | SEK 5.64 |
| 52 Week Low | SEK 0.059 |
| Beta | 1.29 |
| 1 Month Change | -23.31% |
| 3 Month Change | -49.60% |
| 1 Year Change | -98.61% |
| 3 Year Change | -99.60% |
| 5 Year Change | -99.65% |
| Change since IPO | -99.39% |
Recent News & Updates
Recent updates
We Think Scandion Oncology (STO:SCOL) Needs To Drive Business Growth Carefully
Aug 02
Companies Like Scandion Oncology (STO:SCOL) Are In A Position To Invest In Growth
Feb 01Here's Why We're Not Too Worried About Scandion Oncology's (STO:SCOL) Cash Burn Situation
May 26We're Hopeful That Scandion Oncology (NGM:SCOL) Will Use Its Cash Wisely
Jan 06
Shareholder Returns
| SCOL | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | -10.1% | 3.6% | 4.9% |
| 1Y | -98.6% | 14.4% | 13.7% |
Return vs Industry: SCOL underperformed the Swedish Biotechs industry which returned 11.7% over the past year.
Return vs Market: SCOL underperformed the Swedish Market which returned 13.1% over the past year.
Price Volatility
| SCOL volatility | |
|---|---|
| SCOL Average Weekly Movement | 11.7% |
| Biotechs Industry Average Movement | 9.6% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in SE Market | 11.8% |
| 10% least volatile stocks in SE Market | 3.2% |
Stable Share Price: SCOL's share price has been volatile over the past 3 months compared to the Swedish market.
Volatility Over Time: SCOL's weekly volatility has decreased from 22% to 12% over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 4 | Francois Martelet | www.scandiononcology.com |
Scandion Oncology A/S, a clinical-stage biotechnology company, discovers and develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase II clinical trial for the treatment of colorectal cancer; and in Phase I clinical trial for treating pancreatic cancer, as well as in preclinical studies for other cancer indications. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV.
Scandion Oncology A/S Fundamentals Summary
| SCOL fundamental statistics | |
|---|---|
| Market cap | SEK 14.50m |
| Earnings (TTM) | -SEK 49.87m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.3x
P/E RatioIs SCOL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SCOL income statement (TTM) | |
|---|---|
| Revenue | DKK 0 |
| Cost of Revenue | DKK 0 |
| Gross Profit | DKK 0 |
| Other Expenses | DKK 32.47m |
| Earnings | -DKK 32.47m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 27, 2025
| Earnings per share (EPS) | -0.14 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did SCOL perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/21 18:02 |
| End of Day Share Price | 2025/01/21 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Scandion Oncology A/S is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Soo Romanoff | Edison Investment Research |
| Christian Binder | Redeye |